Drug intelligence / Profile preview

FHCT001

Development stage: Phase 1
Lead developer: FullHope Biomedical
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

FHCT001 is an autologous immune cell therapy developed by FullHope Biomedical for the treatment of solid tumors. It consists of dendritic killer cells (DKC), which are rare immune cells that exhibit both innate and adaptive immune functions. The therapy is produced using a proprietary in-vitro cultivation system designed to scale up cell activity and numbers under Good Tissue Practice (GTP) standards. FHCT001 is intended as an adjuvant therapy to provide high specificity against cancer cells with minimal side effects. A Phase 1 clinical trial (NCT02882659) has been completed to evaluate its safety and determine the maximum tolerated dose in patients with metastatic solid tumors.

Other names: Autologous dendritic killer cell therapyDKC therapy

Beyond the preview

Go deeper on FHCT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FHCT001.

Explore the full profile